Squarepoint
RXRX icon

Squarepoint’s Recursion Pharmaceuticals RXRX Stock Holding History

Squarepoint’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,000
Closed -$159K – 4980
2025
Q1 		$159K Buy
+30,000
New +$219K ﹤0.01% 4096

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Squarepoint's RXRX Position: Q2 2026 in Review

Squarepoint increased its Recursion Pharmaceuticals (RXRX) stake by 86% in Q2 2026, buying an estimated $151K and bringing the position to 98,426 shares worth $361K. The position accounts for ﹤0.01% of the portfolio, ranked #3681.

Squarepoint first reported a position in RXRX in Q4 2021 and has held it in 13 quarters since. The position peaked at $3.63M in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Squarepoint held 98,426 shares of Recursion Pharmaceuticals worth $361K as of Q2 2026.
  • Squarepoint bought 45,438 Recursion Pharmaceuticals shares in Q2 2026, an estimated $151K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3681 holding.
  • Squarepoint first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • Squarepoint's Recursion Pharmaceuticals position peaked at $3.63M in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.